[Mood disorders: When should we use repetitive transcranial magnetic stimulation?]

Troubles de l’humeur : quand recourir à la stimulation magnétique transcrânienne ?

Journal

Presse medicale (Paris, France : 1983)
ISSN: 2213-0276
Titre abrégé: Presse Med
Pays: France
ID NLM: 8302490

Informations de publication

Date de publication:
Jun 2019
Historique:
received: 10 08 2018
revised: 30 12 2018
accepted: 31 01 2019
pubmed: 4 6 2019
medline: 3 7 2019
entrez: 4 6 2019
Statut: ppublish

Résumé

Repeated transcranial magnetic stimulation (rTMS) is still a recent treatment in psychiatry. This article aims at updating the clinicians'knowledge about rTMS in the treatment of mood disorders (uni and bipolar depressive disorders, manic/mixed states, suicidal risk, catatonia). It is intended for clinicians who are required to indicate and/or use rTMS in their current practice. rTMShas the highest level of evidence for the treatment of unipolar depression, provided that effective parameters are used, that is to say, for classical high frequency protocols: 20 to 30 sessions, 1000 pulses/session, 5 to 20Hz, and 110 % of the motor threshold. Low frequency protocol are also efficient and well tolerated. The duration of the efficacy varies with relapses rates around 50 % at one year. Pharmacological treatment generally remains associated. With regard to manic states, and mixed states the results are preliminary and limited to a possible reduction in symptoms. In the suicidal risk associated with mood disorders, the interest of rTMS is still to demonstrate, as well as in catatonia. The current place of the rTMS is no longer disputed in the curative treatment of major depressive disorder, preferentially used after one or two lines of antidepressants upstream. Further studies are needed to confirm preliminary positive findings in other aspects of mood disorders.

Identifiants

pubmed: 31155435
pii: S0755-4982(19)30204-0
doi: 10.1016/j.lpm.2019.01.012
pii:
doi:

Types de publication

Journal Article Review

Langues

fre

Sous-ensembles de citation

IM

Pagination

625-646

Informations de copyright

Copyright © 2019 Elsevier Masson SAS. All rights reserved.

Auteurs

Samuel Bulteau (S)

CHU de Nantes, addictology and liaison psychiatry department, 44000 Nantes, France; University of Nantes, university of Tours, Inserm, SPHERE U1246, 44000 Nantes, France.

Charline Guirette (C)

CHU de Nantes, addictology and liaison psychiatry department, 44000 Nantes, France.

Jérôme Brunelin (J)

University of Lyon, Lyon Neuroscience Research Center, ΨR2 Team, Inserm U1028, CNRS UMR5292, 69000 Lyon, France; Lyon 1 university, 69000 Villeurbanne, France; Centre hospitalier Le Vinatier, 69678 Bron, France.

Emmanuel Poulet (E)

Groupement hospitalier centre, pavillon N, service de psychiatrie des urgences, hospices civils de Lyon, 69003 Lyon, France; Lyon 1 university, 69000 Villeurbanne, France; University of Lyon, 69000 Lyon, France; University of Lyon 1, 69000 Villeurbanne, France; Centre hospitalier Le Vinatier, 69678 Bron, France.

Benoît Trojak (B)

University hospital of Dijon, department of psychiatry and addictology, 21079 Dijon, France.

Raphaëlle Richieri (R)

Assistance publique des Hôpitaux de Marseille, CHU Sainte-Marguerite, pôle psychiatrie addictologie pedopsychiatrie, 13000 Marseille, France; Faculté de médecine, laboratoire de santé publique, EA 3279, 13000 Marseille, France.

David Szekely (D)

Centre hospitalier Princesse-Grace, principauté de Monaco, Monaco, Monaco.

Djamila Bennabi (D)

University of Bourgogne Franche-Comté, university hospital of Besancon and FondaMental Foundation, department of clinical psychiatry, EA 481 neurosciences, 25000 Créteil, France.

Antoine Yrondi (A)

CHU Toulouse-Purpan, psychiatric department, 31000 Toulouse, France; University of Toulouse, Toulouse NeuroImaging Center, ToNIC, Inserm, UPS, 31024 Toulouse cedex 3, France.

Maud Rotharmel (M)

Centre hospitalier du Rouvray, service hospitalo-universitaire, 4, rue Paul-Éluard, 76300 Sotteville-lès-Rouen, France; Faculté de médecine pharmacie, Inserm U1079, 76000 Rouen, France.

Thierry Bougerol (T)

CHU de Grenoble, clinique de psychiatrie, pôle neurologie psychiatrie, 38043 Grenoble, France.

Gaëlle Dall'Igna (G)

Centre hospitalier universitaire Grenoble Alpes, pôle de psychiatrie et neurologie, 38000 Grenoble, France; Grenoble institut des neurosciences, GIN, Inserm, U1216, 38000 Grenoble, France.

Jérôme Attal (J)

CHU of Montpellier, hôpital de la colombière, department of adult psychiatry, 34295 Montpellier, France.

René Benadhira (R)

Unité de recherche clinique, EPS Ville Evrrad, pôle G03, 202, avenue Jean-Jaures, 93330 Neuilly/Marne, France.

Noomane Bouaziz (N)

Unité de recherche clinique, EPS Ville Evrrad, pôle G03, 202, avenue Jean-Jaures, 93330 Neuilly/Marne, France; Université de Bourgogne Franche Comté, service de psychiatrie clinique, Centre expert dépression résistante FondaMental, Centre investigation clinique 1431-Inserm, EA 481 neurosciences, 25000 Besançon, France.

Maxime Bubrovszky (M)

EPSM de l'Agglomération lilloise, BP 4, 59871 Saint-André-lez-Lille, France.

Benjamin Calvet (B)

Centre hospitalier Esquirol, unité de recherche et de neurostimulation, 87000 Limoges, France; Centre hospitalier Esquirol, pôle universitaire de psychiatrie de l'adulte et de la personne âgée, 87000 Limoges, France; Institut d'épidemiologie neurologique et de neurologie, Inserm UMR1094, 87000 Limoges, France.

Sonia Dollfus (S)

CHU de Caen, centre Esquirol, service de psychiatrie, 14000 Caen, France; Normandie université, UNICAEN, ISTS, GIP Cyceron, boulevard Henri-Becquerel, 14000 Caen, France; Normandie université, UNICAEN, UFR de médecine (Medical School), 14000 Caen, France.

Jack Foucher (J)

CHU de Strasbourg, université Strasbourg, CNRS, UMR 7357 - ICube - laboratoire des sciences de l'ingénieur, de l'informatique et de l'imagerie and Fédération de médecine translationnelle de Strasbourg (FMTS), 67000 Strasbourg, France; CEntre de neuroModulation non invasive de Strasbourg (CEMNIS), 67000 Strasbourg, France.

Filipe Galvao (F)

Centre hospitalier Le Vinatier, 69678 Bron, France.

Aurélia Gay (A)

University hospital center of Saint-Étienne, university department of psychiatry and addiction, 42055 Saint-Étienne, France; Jean-Monnet university, TAPE Laboratory, EA7423, 42000 Saint-Étienne, France.

Frédéric Haesebaert (F)

Lyon Neuroscience Research Center, PSY-R2 Team, Inserm, U1028, 69000 Lyon, France; CNRS, UMR5292, Lyon Neuroscience Research Center, PSY-R2 Team, 69000 Lyon, France; University Lyon, 69000 Lyon, France; Centre hospitalier le Vinatier, Bâtiment 416, 95, boulevard Pinel, 69678 Bron, France.

Emmanuel Haffen (E)

Université de Bourgogne Franche Comté, centre expert dépression résistante FondaMental, centre investigation clinique 1431, service de psychiatrie clinique, Inserm, EA 481 neurosciences, 25000 Besançon, France.

Isabelle Jalenques (I)

CHU Clermont-Ferrand, université Clermont Auvergne, institut de Psychiatrie-GDR 3557, service de psychiatrie de l'adulte A et psychologie médicale, Centre mémoire de ressources et de recherche, 63000 Clermont-Ferrand, France.

Dominique Januel (D)

Unité de recherche clinique, EPS Ville Evrrad, pôle G03, 202, avenue Jean-Jaures, 93330 Neuilly/Marne, France.

Renaud Jardri (R)

CHU de Lille, université de Lille, hôpital Fontan, plateforme CURE, SCALab, CNRS UMR-9193, 59037 Lille, France.

Bruno Millet (B)

Sorbonne universités, university Pierre-et-Marie-et-Curie, 75000 Paris, France; AP-HP, hôpital Pitié-Salpêtrière, department of psychiatry, 75000 Paris, France.

Clément Nathou (C)

CHU de Caen, centre Esquirol, service de psychiatrie, 14000 Caen, France; Université de Caen, UFR de médecine, 14000 Caen, France; Centre Cycéron, CNRS UMR 6301, ISTCT, ISTS, 14000 Caen, France.

Cecilia Nauczyciel (C)

Université de Rennes 1, EA-4712 behavior and basal ganglia unit, 35000 Rennes, France; Centre hospitalier Guillaume-Régnier, service hospitalo-universitaire de psychiatrie, 35000 Rennes, France.

Marion Plaze (M)

Institut de psychiatrie, centre de psychiatrie & neurosciences, CNRS GDR 3557, Inserm UMR 894, 75000 Paris, France; Université Paris Descartes, Sorbonne Paris Cité, 75000 Paris, France; Centre hospitalier Sainte-Anne, service hospitalo-universitaire, Paris, France.

Fady Rachid (F)

7, place de la Fusterie, 1204 Genève, Suisse.

Jean-Marie Vanelle (JM)

CHU de Nantes, addictology and liaison psychiatry department, 44000 Nantes, France.

Anne Sauvaget (A)

CHU de Nantes, addictology and liaison psychiatry department, 44000 Nantes, France; University of Nantes, faculty of sport sciences, laboratory « Movement, Interactions, Performance » (EA 4334), 44000 Nantes, France. Electronic address: anne.sauvaget@chu-nantes.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH